Ravi Salgia to Peptides, Cyclic
This is a "connection" page, showing publications Ravi Salgia has written about Peptides, Cyclic.
Connection Strength
1.178
-
Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study. Invest New Drugs. 2017 06; 35(3):334-344.
Score: 0.593
-
A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer. Lung Cancer. 2017 03; 105:7-13.
Score: 0.585